Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of BETAPLUS PHARMA is 0.7% (low). The company has been active since 2002 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Based on State Gazette and CBE data.
Financials
No processed annual-account figures available.
To financials
People & board
9 mandates
9
active directors
Beryle ZanyDirectorFrancois JamarDirectorXavier DefourtDirector+6 in history
All directors & mandates Publicationslatest 09-04-2026
37
publications in the State Gazette1 director appointed, 1 resigningAll publications & acts Network & structure
No network or structure data processed.
To structure
Trust signals
3 signalsLong-established
Founded in 2002 — 23 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
0 events
No administrative flags
Bankruptcy probability (12 mo)
Checked model v1 · free for everyone0.7%
Low
0%0,5%1,5%4%10%≥25%
Higher-failure-rate region
+Long track record
−Lower-risk legal form
−
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Company registry (CBE)
Crossroads BankActivities
Vervaardiging van farmaceutische grondstoffen21100Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen24421Vervaardiging van overige farmaceutische producten21209
Primary activity highlighted.
Names & trade names
| Legal nameFR | BETAPLUS PHARMA |
| AbbreviationFR | betaplus |
Registered office
Hippokrateslaan 10 bus 1527
1200 Sint-Lambrechts-Woluwe, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.